Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 5
Submit an article Journal homepage
297
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Danai Dimaa Hematology/Oncology Division, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3587-7975View further author information
ORCID Icon,
Xiao Hub Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-9036-8455View further author information
ORCID Icon,
Joshua Dowerb Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USAView further author information
,
Diana Zhangc Internal Medicine Division, Massachusetts General Hospital, Boston, MA, USAView further author information
,
Raymond Comenzod The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USAView further author information
&
Cindy Vargad The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USAView further author information
Pages 1246-1250 | Received 10 Oct 2021, Accepted 06 Dec 2021, Published online: 02 Jan 2022

References

  • Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
  • Dima D, Dower J, Comenzo RL, et al. Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2020;12:7891–7903.
  • Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
  • Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
  • Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632–642.
  • Van de Wyngaert Z, Carpentier B, Pascal L, et al. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol. 2020;188(3):e24–e27.
  • Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol. 2019;37(5):595–600.
  • Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. Br J Haematol. 2019;185(2):342–344.
  • Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902.
  • Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541–1547.
  • Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–1540.
  • Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33(2):531–536.
  • Chung A, Kaufman GP, Sidana S, et al. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Adv. 2020;4(3):458–466.
  • Shragai T, Gatt M, Lavie N, et al. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: a multisite study and systematic literature review. Eur J Haematol. 2021;106(2):184–195.
  • Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid. 2020;27(3):163–167.
  • Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020;95(8):900–905.
  • Kimmich CR, Terzer T, Benner A, et al. Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: high efficacy, relevant toxicity and main adverse effect of gain 1q21. Am J Hematol. 2021;96(7):E253–E257.
  • Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):1517–1530.
  • Godara A, Toskic D, Albanese J, et al. Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. Am J Hematol. 2021;96:E20–E23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.